Patel Dinesh V PH D's Form 4 filing
Protagonist Therapeutics, Inc (PTGX) · filed Dec 15, 2023
- Accession no.
- 0001104659-23-126419
- Filed
- Dec 15, 2023
- Trade date
- Dec 13, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction. Open-market sales total $1.51M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Patel Dinesh V PH DCIK 0001120477 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 13, 2023 | Common Stock | SSaleDisposed | −75,000 | $20.08F2 | −$1,506,000 | 534,347 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.20. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.